KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Share-based Compensation (2017 - 2025)

Bionano Genomics' Share-based Compensation history spans 7 years, with the latest figure at $941000.0 for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 57.27% year-over-year to $941000.0; the TTM value through Sep 2025 reached $5.5 million, down 50.38%, while the annual FY2024 figure was $9.7 million, 35.85% down from the prior year.
  • Share-based Compensation for Q3 2025 was $941000.0 at Bionano Genomics, down from $1.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $9.7 million in Q4 2021 and bottomed at -$2.1 million in Q3 2021.
  • The 5-year median for Share-based Compensation is $3.0 million (2024), against an average of $3.2 million.
  • The largest annual shift saw Share-based Compensation tumbled 222.26% in 2021 before it soared 1275.2% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $9.7 million in 2021, then tumbled by 43.54% to $5.5 million in 2022, then tumbled by 38.46% to $3.4 million in 2023, then plummeted by 42.59% to $1.9 million in 2024, then plummeted by 51.39% to $941000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Share-based Compensation are $941000.0 (Q3 2025), $1.1 million (Q2 2025), and $1.6 million (Q1 2025).